News WuXi Biologics (Cayman) Inc. OTC Markets

Stocks

WXXW.Y

US98260N1081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:59:59 2026-06-09 pm EDT			5-day change	1st Jan Change
7.600 ^USD	-2.31%		-14.36%	-5.00%

Jun. 05	Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub	CI
May. 31	Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth	RE

All News

Mentions Relevance

Jun. 08	WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards	PR
Jun. 05	Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub	CI
Jun. 04	WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility	PR
Jun. 04	WuXi Biologics Cayman : Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility	PU
Jun. 02	WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year	PR
Jun. 01	WuXi Biologics Cayman : Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year	PU
May. 31	Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth	RE
May. 27	WuXi Vaccines Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing	AQ
May. 27	WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities	PR
May. 27	Wuxi Biologics Achieves Gmp Release of 18Th Drug Product Facility and Advances Integrated Drug Substance to Drug Product Capabilities	CI
May. 25	WuXi Biologics to Conduct Up to $400 Million Share Buyback; Shares Up 4%	MT
May. 25	Wuxi Biologics to repurchase shares up to US$400 million in open market	RE
May. 25	WuXi Biologics Plans to Buy Back Up to US$400 Million of Shares	DJ
Apr. 29	WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access	PR
Apr. 29	WuXi Biologics Cayman : Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access	PU
Apr. 24	WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival	PR
Apr. 24	WuXi Biologics Achieves Structural Completion and Key Equipment Arrival At Chengdu Microbial Commercial Manufacturing Site	CI
Apr. 23	WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics	CI
Apr. 23	WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics	PR
Apr. 17	WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year	PR
Apr. 14	WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing	PR
Mar. 30	WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year	PR
Mar. 25	WuXi Biologics Inc., 2025 Earnings Call, Mar 25, 2026
Mar. 25	WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture	PR
Mar. 24	WuXi Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI